Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any).
about
Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: retrospective analysis over 16 years at one Chinese center.Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.Preoperative management in patients with Graves' disease.NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features.Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy.Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves' disease model.Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism
P2860
Q38942929-432692E6-459B-4437-9C40-3E06378CCCF5Q38972962-B1FD57F7-55F0-4A30-92BA-1B885B3EEF3DQ40405974-FA0979DF-EF6C-4410-B163-744E36196C4DQ42369871-9A337BF1-2C9D-4719-AA6F-8286B4A1EF2AQ47122099-244A1D87-762E-4888-86FB-7A069CB56E8FQ47212889-387DE232-3AEA-44A1-85EE-51F418AC7B87Q47627780-6975A614-79BC-4B04-8A6D-6A9FFD42FD30Q50086190-04E96472-6E85-4D05-B033-778626F23C07Q50254727-F85CE506-8148-4219-ADB7-B29B42D177B6Q51073539-8D84AA83-256C-4D03-9DC3-90943C11C236Q52624186-5770DA5F-3858-4983-9368-4A8E16D34860Q53192241-482A1A21-1BA9-4B29-BAB1-F84EAEE8927AQ53207209-A1070333-B849-4CDC-A6FB-5B24A77DEF11Q57136607-95DFFA0E-D057-4553-BF1E-7413B97CDCC4
P2860
Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Management of hyperthyroidism ...... uestions and answers (if any).
@en
type
label
Management of hyperthyroidism ...... uestions and answers (if any).
@en
prefLabel
Management of hyperthyroidism ...... uestions and answers (if any).
@en
P2093
P2860
P1476
Management of hyperthyroidism ...... uestions and answers (if any).
@en
P2093
P2860
P2888
P304
P356
10.1007/S40618-016-0505-X
P577
2016-06-18T00:00:00Z
P6179
1009270396